FDA approves Bydureon, the first once-weekly GLP-1

The Food and Drug Administration approved Bydureon, an extended-release version of the GLP-1 drug exenatide, on January 27, 2012 under new drug application number 022200. It was the first GLP-1 receptor agonist that patients could inject once a week instead of once or twice a day. The drug uses tiny polymer microspheres that hold the medicine and release it slowly after injection.

A note on sourcing: the only document provided with this development is a 2025 Federal Register notice from FDA about withdrawing approval of unmarketed drug applications ^[1]. That notice does not contain the 2012 approval package, so the clinical trial results, labeled uses, dosing details and safety warnings that went with Bydureon's approval are not available in the material here and are not summarized below. Readers who want those specifics would need FDA's approval documents and the product label, which are not part of this source set.

What the shift to weekly dosing changed

Before this approval, GLP-1 therapy meant daily — in some cases twice-daily — injections. Moving to a single weekly injection cut the number of shots from hundreds a year to about 52. That change in schedule became the template for the GLP-1 drugs that dominate the market today, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), both of which are weekly injections. The specific approval dates, trial data and comparative results for those later drugs are not covered by the source provided here ^[1].

How FDA retires an old drug application

The one document in this source set illustrates the back end of a drug's life cycle. On August 4, 2025, FDA published a notice withdrawing approval of 39 new drug applications from multiple companies, effective September 3, 2025 ^[1]. The agency said the applicants "notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn" ^[1].

That process runs under 21 CFR 314.150(c) ^[1]. By making the request, the companies also waived their chance for a hearing, and FDA noted that withdrawal under that provision "is without prejudice to refiling" — meaning a company could come back later and seek approval again ^[1]. The notice carries docket number FDA-2025-N-2422 and citation 90 FR 36440, and a correction to it was published on October 3, 2025 ^[1]. The published table lists older products such as Hexadrol (dexamethasone), Vivactil (protriptyline), Sinequan (doxepin) and Loxitane (loxapine) ^[1]. The portion of the table available in this source does not show NDA 022200, so whether Bydureon's application was part of this particular batch is not established by the document provided.

Why it matters for patients

Two practical points come out of this. First, the once-weekly schedule that most GLP-1 users now take for granted started with a specific product and a specific approval in January 2012. Understanding that history helps explain why weekly dosing, not daily, is the default design for newer drugs in this class.

Second, an FDA "withdrawal of approval" notice does not automatically mean a drug was found unsafe. In the August 2025 notice, the reason given was that the manufacturers told FDA the products were no longer marketed and asked that the applications be withdrawn ^[1]. Commercial decisions, not safety findings, drove those specific withdrawals as described in the notice. If a medicine someone takes disappears from pharmacy shelves, the reason may be a business choice rather than a new risk — though the source here does not address any individual product beyond those it lists.

What happens next

The dated milestones documented in the available source are the notice's publication on August 4, 2025, the withdrawal taking effect September 3, 2025, and a correction published October 3, 2025 ^[1]. Comments on that docket are closed ^[1]. Any current marketing status for exenatide extended-release products is not addressed in the sources provided.